ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and RAS-targeted therapies to the growing influence of Chinese biotech on the global stage, this year’s meeting showcased the evolving future of cancer care. Listen to the recap: https://www.fiercepharma.com/pharma/behind-headlines-asco-2026
More Tips From The Bandish Group
Speed matters in oncology drug development—but strategy matters even more.
◆
A recent Fierce Biotech article explores how the FDA’s Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations can help…
Successful employees have 6 things in common
◆
Work is a necessity for most of us, but life is too short to spend it weighed down by unhappiness…